Percutaneous chemoperfusion with complete venous isolation and charcoal hemoperfusion for treatment of abdominal cancer

我们开发了一个新的治疗系统，用于高剂量的内部化学疗法，具有完整的原始隔离和碳半导体融合，以尝试最大限度地减少肿瘤药物的输送，并在同一时间，最小限度地减少系统毒性。本研究是为在肝脏、面包屑和Pelvis中开发多形态治疗策略而设计的。在第一年，我们建立了一种全隔离的liver chemoperfusion （PILP）的单一催化剂技术，并在同一患者上启动了一个重复治疗的临床试验。我们的发现清楚地表明，重复的治疗方法在恶性肝脏肿瘤中花费了更多的时间，以及这种治疗方法的治疗指数。在另一方面，我们启动了与肾上腺素低阴道Caval Isolation和碳水化合物Hemopperfusion的第二阶段临床试验（IVCI和CHP）用于高级uterine癌症。在补充中，我们完成了一项关于门户绝缘隔离和碳水化合物的实验研究 ... More N代表肺癌。在第二阶段，我们引入了一种新的治疗协议组合，重复的PILP，即一种带有低剂量间歇性流感的诱导疗法，即用于患者与高级肝炎细胞瘤的维护疗法。对于IVCL·CHP，一项新补充化疗协议被设计为实现高级uterine癌症的下行阶段。三名患有泌尿系统癌症的患者已经被治疗过这个协议。一个病人有一个完整的肿瘤坏死，作为手术后的微观分析，两个病人有部分反应。因此，我们确认了这种治疗对小儿麻痹症的有效性。在第三年，我们试图用这种治疗治疗来治疗肺癌的肿瘤。However，我们不能用病人来表达治疗。在患有高级乙型肝炎肉瘤的患者中，我们评估了PILP使用的多种治疗的长期结果。结果表明，5年的存活率达到40%，4个30个患者在2至4年的范围内无长期肿瘤存活。我们还治疗了15名患有彩色肝炎的患者，并展示了PILP对疾病的有效性。基于这些结果，我们结合了我们的方法，为患者提供了一种有效的治疗选择，用于恶性肿瘤。Less（低）

We developed a new treatment system for high-dose intraarterial chemotherapy with complete venous isolation and charcoal hemoperfusion in an attempt to maximize tumor drug delivery and, at the same time, to minimize systemic toxicity. This study was designed to develop multimodal treatment strategies for malignant abdominal tumors in the liver, the pancreas, and the pelvis. In the first year, we established a single catheter technique of percutaneous isolated liver chemoperfusion (PILP) and initiated a clinical trial of repeated treatment on the same patient. Our findings clearly showed that repeated treatments further expand the therapeutic index of this treatment for malignant liver tumors. On the other hand, we initiated the phase II clinical trial of pelvic chemoperfusion with infrarenal inferior vena caval isolation and charcoal hemoperfusion (IVCI・CHP) for advanced uterine cancer. In addition, we completed an experimental study on portal venous isolation and charcoal hemoperfusio … More n for pancreatic cancer. In the second vear, we introduced a new treatment protocol combining repeated PILP as the inductive therapy with low-dose intermittent infusions as the maintenance therapy for patients with advanced hepatoccellular carcinoma. For IVCL・CHP,a protocol of neoadjuvant chemotherapy was designed to achieve down-staging of advanced uterine cancer. Three patients with uterine cancer have been treated with this protocol. One patient had a complete tumor necrosis, as proved microscopically after operation, and two had a partial response. Thus we confirmed the efficacy of this treatment for pelvic tumors. In the third year, we attempted to treat pancreatic tumor with this treatment.However, we could not have patients with indication for the treatment. In patients with advanced hepatocellular carcinoma, we assessed the long-term results of the multimodal treatment with use of PILP.The results indicated that 5-year survival rate reached 40% and that 4 of 30 patients had a long-term tumor-free survival in a range of 2 to 4 years. We have also treated 15 patients with colorectal hepatic metastases, and have shown the efficacy of PILP for the disease. Based on these results, we concluded that our method offers an effective therapeutic option for patients with malignant abdominal tumors. Less